翰森製藥現漲逾3% B7-H3靶向抗體藥物偶聯物HS-20093獲FDA突破性療法認定

新浪港股

01-09

熱點欄目自選股數據中心行情中心資金流向模擬交易

客戶端

　　翰森製藥（03692）早盤上漲2.84%，現報16.68港元，成交額1482.02萬港元。

　　1月7日，翰森製藥公佈，GSK就GSK5764227（GSK’227，亦稱 HS-20093）獲美國食品藥品監督管理局（FDA）授予突破性療法認定（BTD），此B7-H3靶向抗體藥物偶聯物（ADC）正在評估用於治療既往經二線及以上治療進展的復發或難治性骨肉瘤（骨癌）成人患者。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：盧昱君

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2502662037"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502662037\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2502662037?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-01-09 10:13","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2502662037","market":"other","top_or_hot":-1,"title":"翰森製藥現漲逾3% B7-H3靶向抗體藥物偶聯物HS-20093獲FDA突破性療法認定","media":"新浪港股","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/03692.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/03692\">翰森製藥</a></span><span></span>（03692）早盤上漲2.84%，現報16.68港元，成交額1482.02萬港元。</p>\n<p>　　1月7日，翰森製藥公佈，GSK就GSK5764227（GSK’227，亦稱 HS-20093）獲美國食品藥品監督管理局（FDA）授予突破性療法認定（BTD），此B7-H3靶向抗體藥物偶聯物（ADC）正在評估用於治療既往經二線及以上治療進展的復發或難治性骨肉瘤（骨癌）成人患者。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>翰森製藥現漲逾3% B7-H3靶向抗體藥物偶聯物HS-20093獲FDA突破性療法認定</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰森製藥現漲逾3% B7-H3靶向抗體藥物偶聯物HS-20093獲FDA突破性療法認定\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">新浪港股</strong><span class=\"h-time small\">2025-01-09 10:13</span>\n</p>\n</header>\n<article>\n<div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/03692.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/03692\">翰森製藥</a></span><span></span>（03692）早盤上漲2.84%，現報16.68港元，成交額1482.02萬港元。</p>\n<p>　　1月7日，翰森製藥公佈，GSK就GSK5764227（GSK’227，亦稱 HS-20093）獲美國食品藥品監督管理局（FDA）授予突破性療法認定（BTD），此B7-H3靶向抗體藥物偶聯物（ADC）正在評估用於治療既往經二線及以上治療進展的復發或難治性骨肉瘤（骨癌）成人患者。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-01-09/doc-ineeitpf3328807.shtml\">新浪港股</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-01-09/doc-ineeitpf3328807.shtml","article_id":"2502662037","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502662037","pubTimestamp":1736388780,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　翰森製藥（03692）早盤上漲2.84%，現報16.68港元，成交額1482.02萬港元。\n　　1月7日，翰森製藥公佈，GSK就GSK5764227（GSK’227，亦稱 HS-20093）獲美國食品藥品監督管理局（FDA）授予突破性療法認定（BTD），此B7-H3靶向抗體藥物偶聯物（ADC）正在評估用於治療既往經二線及以上治療進展的復發或難治性骨肉瘤（骨癌）成人患者。\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","BK1583":"高瓴概念","BK1191":"制药","03692":"翰森制药"},"translate_title":"Hansoh Pharmaceuticals is now up more than 3% B7-H3 targeted antibody drug conjugate HS-20093 received FDA breakthrough therapy designation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　翰森製藥（03692）早盤上漲2.84%，現報16.68港元，成交額1482.02萬港元。\n　　1月7日，翰森製藥公佈，GSK就GSK5764227（GSK’227，亦稱 HS-20093）獲美國食品藥品監督管理局（FDA）授予突破性療法認定（BTD），此B7-H3靶向抗體藥物偶聯物（ADC）正在評估用於治療既往經二線及以上治療進展的復發或難治性骨肉瘤（骨癌）成人患者。\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0}}}